How Should We Measure the Effectiveness of our Corporate University Programs?

As a result of the sub-optimal performance of recent graduates, the corporate university was created. Now, the corporate university is a central part of many learning organizations. Although firms with the largest investments in their people have proven to outperform other firms by 17% to 35% on the Standard and Poor’s index, the fact is corporate universities still cost money, a lot of it. So, numerous firms have sought out to forge methods of measuring the effectiveness of corporate universities to determine the business impact and the potential need of improvement. However, determining what to measure and how to do so has proven to be a challenging task, one that many firms haven’t yet tackled. For instance, one study found that 39% of organizations spend less than 1% their training budget on measurement and 94.3% of firms spend less than 5%, although measurement is crucial to improving the success of a corporate university. Thus, this paper will present a variety of the best approaches that can be used to measure the efficacy of a corporate university

What Ways Can We Use Big Data to Offer More Personalized and Tailored HR Services to our Employees?

Big data analytics—analytic techniques operating on big data—is continuing to disrupt the way decision-making is occurring. Instead of relying on intuition, decisions are made based on statistical analysis, emerging technologies and massive amounts of current and historical data. Predictive analytics, which will be featured in much of the research below, is a type of big data analytics that predicts an outcome by correlating the relationships of various factors. These predictions can be made utilizing a variety of organized structured data and disorganized unstructured data (i.e. social media posts, surveys, etc.

What are the Latest Trends in Career Pathing Models as Well as the Most Effective Ways to Accelerate High Potential Development?

The war for talent is raging, making attracting, retaining, and developing high-performers more challenging than ever. Many of the “Baby Boomer” executives will be retiring in the near future, and only 15% of organizations in North America and Asia believe they have sufficient qualified successors for key positions. Additionally, 25% of surveyed organizations said they fail to keep top-performers, further illustrating the urgency and importance of the need to design optimal programs for developing future leaders. Thus, the content below will provide insight into the factors that make development program for “high potentials” successful

Impalpable Breast Cancer and Service Delivery during the COVID-19 Pandemic : the Role of Radiofrequency Tag localization

Funding Information: The authors would like to thank Friends of Anchor for their generous grant that enabled the trial of RF tags in Aberdeen, and all the staff in the Unit at Aberdeen Royal Infirmary and BMI Albyn Hospital for making this possible.Peer reviewedPublisher PD

The impact of immediate breast reconstruction on the time to delivery of adjuvant therapy: the iBRA-2 study

Background: Immediate breast reconstruction (IBR) is routinely offered to improve quality-of-life for women requiring mastectomy, but there are concerns that more complex surgery may delay adjuvant oncological treatments and compromise long-term outcomes. High-quality evidence is lacking. The iBRA-2 study aimed to investigate the impact of IBR on time to adjuvant therapy. Methods: Consecutive women undergoing mastectomy ± IBR for breast cancer July–December, 2016 were included. Patient demographics, operative, oncological and complication data were collected. Time from last definitive cancer surgery to first adjuvant treatment for patients undergoing mastectomy ± IBR were compared and risk factors associated with delays explored. Results: A total of 2540 patients were recruited from 76 centres; 1008 (39.7%) underwent IBR (implant-only [n = 675, 26.6%]; pedicled flaps [n = 105,4.1%] and free-flaps [n = 228, 8.9%]). Complications requiring re-admission or re-operation were significantly more common in patients undergoing IBR than those receiving mastectomy. Adjuvant chemotherapy or radiotherapy was required by 1235 (48.6%) patients. No clinically significant differences were seen in time to adjuvant therapy between patient groups but major complications irrespective of surgery received were significantly associated with treatment delays. Conclusions: IBR does not result in clinically significant delays to adjuvant therapy, but post-operative complications are associated with treatment delays. Strategies to minimise complications, including careful patient selection, are required to improve outcomes for patients

Breast cancer management pathways during the COVID-19 pandemic: outcomes from the UK ‘Alert Level 4’ phase of the B-MaP-C study

Abstract: Background: The B-MaP-C study aimed to determine alterations to breast cancer (BC) management during the peak transmission period of the UK COVID-19 pandemic and the potential impact of these treatment decisions. Methods: This was a national cohort study of patients with early BC undergoing multidisciplinary team (MDT)-guided treatment recommendations during the pandemic, designated ‘standard’ or ‘COVID-altered’, in the preoperative, operative and post-operative setting. Findings: Of 3776 patients (from 64 UK units) in the study, 2246 (59%) had ‘COVID-altered’ management. ‘Bridging’ endocrine therapy was used (n = 951) where theatre capacity was reduced. There was increasing access to COVID-19 low-risk theatres during the study period (59%). In line with national guidance, immediate breast reconstruction was avoided (n = 299). Where adjuvant chemotherapy was omitted (n = 81), the median benefit was only 3% (IQR 2–9%) using ‘NHS Predict’. There was the rapid adoption of new evidence-based hypofractionated radiotherapy (n = 781, from 46 units). Only 14 patients (1%) tested positive for SARS-CoV-2 during their treatment journey. Conclusions: The majority of ‘COVID-altered’ management decisions were largely in line with pre-COVID evidence-based guidelines, implying that breast cancer survival outcomes are unlikely to be negatively impacted by the pandemic. However, in this study, the potential impact of delays to BC presentation or diagnosis remains unknown